Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

Giulia Marchetti,1 Annika Taithongchai,2 Dudley Robinson2 1Urogynaecology Department, Irmandade de Misericórdia da Santa Casa de São Paulo, Sao Paulo, Brazil; 2Urogynaecology Department, King’s College Hospital, London, UKCorrespondence: Dudley Robinson, Email Dudley.robinson@nhs.netAbstract: Vulvar vaginal atrophy is a common condition affecting postmenopausal women, significantly impacting their quality of life. Fortunately, various treatment options are available, ranging from hormonal to non-hormonal therapies. Ospemifene has emerged as a promising non-hormonal alternative for managing vulvar vaginal atrophy. Its targeted approach, unique mechanism of action, favorable safety profile particularly for breast tissue, and efficacy make it a valuable option for women seeking relief from symptoms such as vaginal pain, dryness and dyspareunia and cannot receive estrogen supplementations. This is particularly the case for breast cancer survivors or women with a significant family history of estrogen-dependent cancers. Hence, tailored treatment plans, considering individual preferences and health circumstances, are essential in optimizing outcomes and improving the overall well-being of affected individuals.Keywords: ospemifene, vulvovaginal atrophy, genitourinary syndrome of menopause, breast cancer, detrusor overactivity